The common misconception

This paper contains a sentence that I think every heart failure patient should hear at least once.

"A common misconception is that management success is achieved when patients are clinically stable or have mild symptoms."

The authors go on to say that these patients may progress despite apparently optimal treatment.

Staying out of hospital feels like winning. It is a good outcome. But it is not the whole goal, because heart failure can keep advancing quietly while you feel fine.

Silent remodelling

The mechanism is called ventricular remodelling.

When the heart is injured or overloaded, the neurohormonal systems from Part 3 switch on: the renin-angiotensin-aldosterone system and the sympathetic nervous system. Among other things, they drive production of angiotensin II and aldosterone. Both of these cause the heart muscle to thicken and scar (hypertrophy and fibrosis).

Over time the ventricle changes shape. It enlarges, becomes rounder, and pumps less efficiently. That structural change then feeds back into worse function, worse pressures and eventually symptoms.

The paper makes an important point: structural remodelling often happens independently of clinical or haemodynamic deterioration. The heart can be reshaping itself for the worse while symptoms and pressures look unchanged. This process carries a higher risk of death even without obvious symptoms.

The good news: remodelling can reverse

This is the positive side of the story, and it is a big one.

The paper lists therapies that have been shown to have favourable effects on remodelling:

  • ACE inhibitors
  • Beta-blockers
  • Sacubitril/valsartan
  • SGLT2 inhibitors
  • Cardiac resynchronisation therapy
  • Left ventricular assist devices

The authors describe the drug classes as life saving in heart failure with reduced ejection fraction. A large analysis of randomised trials found a significant link between how much a drug or device improves remodelling and how much it improves outcomes.

In other words, when a treatment helps the heart return toward a more normal shape, people tend to live longer and stay out of hospital. That is why reverse remodelling is often used as a stand-in measure for whether a treatment is working.

What the paper's own data shows

This is where the phenotype idea earns its keep.

The Italian Society of Cardiology's Heart Failure Study Group looked at 727 ambulatory patients with reduced ejection fraction treated with sacubitril/valsartan. They sorted them by their echo-derived profile and followed them.

Reverse remodelling was defined as a more than 15% reduction in the end-systolic volume index, a measure of how large the ventricle is at the end of each squeeze.

The pattern was clear:

  • Warm and dry patients (normal flow, normal pressures) had a higher rate of reverse remodelling.
  • They were more likely to reach the target dose of 97 mg/103 mg twice daily.
  • They were more likely to be taking the other heart failure drugs as well.
  • They were less likely to stop the drug due to side effects.
  • They had fewer adverse events.
  • Patients with persistently raised filling pressures showed less reverse remodelling.

A second study from the same group found that treatment with sacubitril/valsartan improved haemodynamics, with better forward flow and lower filling pressures, and restored the warm and dry profile in a substantial share of patients. The bigger the dose achieved, the bigger the improvement.

And the key result: getting back to warm and dry was associated with a significant reduction in death or heart failure rehospitalisation.

The profile can change

This is perhaps the most encouraging thing in the paper. Your profile is not fixed.

The authors are explicit that a patient's haemodynamic classification is not static. It can change with disease progression, and it can change with treatment. That is why they argue for repeated assessment and re-classification over time.

Someone who is warm and wet today, treated properly, can become warm and dry. That shift goes along with better outcomes.

Why this should change how you think about "doing fine"

If you have heart failure and you feel stable, that is genuinely good. But it is worth asking a few extra questions to make sure stable really means stable:

Has my ventricle been remeasured recently? Changes in its size over time are one of the clearest signs of whether treatment is working.

Am I on target doses of my heart failure medications? The data in this paper links reaching target doses with better remodelling. Many patients stay on starter doses longer than they need to.

Which profile am I in now, and has it changed? If your team uses this framework, it is a simple question. If they do not, asking about your filling pressures and output gets to the same place.

Has my natriuretic peptide level come down to my dry level and stayed there? Part 4 explained why this number matters.

The takeaway

The idea behind this part is simple. Feeling stable is the minimum, not the goal. The goal is a heart that is gradually getting back toward normal shape and function, and the evidence here says that is possible for many people, especially those who can reach and tolerate full treatment.

Part 7 now turns the critical eye on this paper, because the framework is attractive and it also has real weaknesses.

This series discusses a peer-reviewed clinical review. Nothing here is medical advice. Heart failure treatment should always be guided by your own cardiology team.